Clinical Trial Update: A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma [Phase 1]

View source ↗

Summary

Pfizer is conducting a Phase 1 study of mevrometostat for relapsed/refractory small cell lung cancer, metastatic castration-resistant prostate cancer, and folli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Follicular Lymphoma
• Small Cell Lung Cancer

Drugs mentioned

• Mevrometostat (Mevrometostat)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC) | Phase 1 | Status: RECRUITING